Schmerz. 2022 Jan 18; doi: 10.1007/s00482-021-00613-x. Epub 2022 Jan 18.

[CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?].

Schmerz (Berlin, Germany)

[Article in German]
Till Hamann, Florian Rimmele, Tim Patrick Jürgens

PMID: 35041064 DOI: 10.1007/s00482-021-00613-x

Abstract

Migraine is associated with a high individual level of suffering. Therefore, an effective preventive treatment is highly important. The spectrum of classical prophylactic drugs has now been expanded to include monoclonal antibodies against calcitonin gene-related peptide (CGRP) and its receptor. These antibodies have shown reliable efficacy compared to placebo and a rapid onset of action with a low rate of side effects and negligible interactions in pivotal studies. Recently, the efficacy of the antibody was shown in many studies even on drug-refractory migraine and migraine associated with medication overuse. Comprehensive head to head comparisons with previously established drugs and among the antibodies are not yet available; however, initial studies suggest better tolerability and efficacy compared to conventional drugs and other antibodies. The role of antibodies in established treatment cascades still needs to be clarified.

© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Keywords: Antibodies, monoclonal; Calcitonin gene-related peptide; Good respond; Migraine disorders, refractory; Prescription drug overuse

References

1. Göbel H (2012) Migräne. In: Erfolgreich gegen Kopfschmerzen und Migräne. Springer, Berlin, Heidelberg, S 55–232 - PubMed
2. Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56 - PubMed
3. Lassen LH, Ashina M (1997) Nitric oxide synthase inhibition in migraine. Lancet 349:401–402 - PubMed
4. Jonas V, Lin CR, Kawashima E, Semon D, Swanson LW, Mermod JJ, Evans RM, Rosenfeld MG (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240–244 - PubMed
5. Juaneda C, Dumont Y, Quirion R (2000) The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci 21:432–438 - PubMed
6. Sternini C (1992) Enteric and visceral afferent CGRP neurons: targets of innervation and differential expression patterns. Ann NY Acad Sci 657:170–186 - PubMed
7. Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR (2004) Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 500(1-3):315–330 - PubMed
8. Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17:533–585 - PubMed
9. Edvinsson L, Ekman R, Jansen I, McCulloch J, Uddman R (1987) Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7:720–728 - PubMed
10. Amara SG, Arriza JL, Leff SE, Swanson LW, Evans RM, Rosenfeld MG (1985) Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229:1094–1097 - PubMed
11. Jansen-Olesen I, Mortensen A, Edvinsson L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16:310–316 - PubMed
12. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL (2007) Neuron–glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47:1008–1023 - PubMed
13. Vause CV, Durham PL (2009) CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem 110:811–821 - PubMed
14. Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Jamaluddin MA, Russo AF, Hay DL (2015) A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2(6):595–608 - PubMed
15. Russo AF (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533–552 - PubMed
16. Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I, Guglielmetti M et al (2019) CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 20:27. https://doi.org/10.1186/s10194-019-0979-y - PubMed
17. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine—current understanding and treatment. N Engl J Med 346:257–270 - PubMed
18. Limmroth V (2002) How do sumatriptan and co. work? The action mechanisms of triptans. Pharm Unserer Zeit 31:458 - PubMed
19. Pervez H, Khemani L, Khan MA, Seedat AM, Roshan F (2020) Calcitonin gene-related peptide antagonists as a savior in episodic and chronic migraine: a review. Cureus 12(6):e8711 - PubMed
20. Diener H‑C, Förderreuther S, Gaul C, Giese F, Hamann T, Holle-Lee D, Jürgens TP, Kamm K, Kraya T, Lampl C (2020) Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor, Ergänzung der S1-Leitlinie Therapie der Migräneattacke und Prophylaxe der Migräne. DGNeurologie 3:124–128 - PubMed
21. Diener H‑C, May A et al (2019) Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor, Ergänzung der S1-Leitlinie Therapie der Migräneattacke und Prophylaxe der Migräne. Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie, (Online: www.dgn.org/leitlinien ) - PubMed
22. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123–2132 - PubMed
23. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026–1037 - PubMed
24. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:1999–2008 - PubMed
25. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE‑1 randomized clinical trial. JAMA Neurol 75(9):1080–1088 - PubMed
26. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE‑2 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442–1454 - PubMed
27. Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241–254 - PubMed
28. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434 - PubMed
29. Detke HC, Goadsby PJ, Shufang W, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211–e2221 - PubMed
30. Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE‑2. Neurology 94:e1365–e1377 - PubMed
31. Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:e2309–e2320 - PubMed
32. Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM (2021) Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41:340–352 - PubMed
33. Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE‑2. Headache 61(1):125–136 - PubMed
34. Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114 - PubMed
35. Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35 - PubMed
36. Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814–825. https://doi.org/10.1016/S1474-4422(20)30279-9 - PubMed
37. Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030–1040 - PubMed
38. Reuter U, Goadsby PJ, Lanteri-Minet M, Shihua W, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280–2287 - PubMed
39. Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40(6):543–553 - PubMed
40. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6 - PubMed
41. Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, Sacco S (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99 - PubMed
42. DMKG (2018) Informationen der DMKG zum Einsatz monoklonaler Antikörper in der Migräneprophylaxe - PubMed
43. Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G, Boudreau GP, McAllister P, Vu T, Zhang F, Cheng S, Picard H, Wen S, Kahn J, Klatt J, Mikol D (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 19(1):92 - PubMed
44. Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E (2021) Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 22:15 - PubMed
45. Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y (2019) Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache 59(10):1743–1752 - PubMed
46. Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R (2021) Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 325(23):2348–2356 - PubMed
47. Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gandolla A, Raffaelli B, Reuter U, Neeb L (2021) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. J Headache Pain 22(Suppl 1):P328 (The International Headache Congress—IHS and EHF Joint Congress 2021) - PubMed
48. Morollón N, Belvís R, De Dios A, Pagès A, Massip M (2021) What if a monoclonal antibody doesn’t work as a migraine preventive treatment? Description of the experience in switching between monoclonals antibodies in a Headache Unit. J Headache Pain 22(Suppl 1):P291 (The International Headache Congress—IHS and EHF Joint Congress 2021) - PubMed
49. Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. https://doi.org/10.1177/03331024211046617 - PubMed
50. Stauffer VL, Shufang W, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK (2019) Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache 59:834–847 - PubMed
51. Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Reuter U (2021) Migraine evolution after discontinuation of preventive treatment with CGPR-(receptor) antibodies: a prospective, longitudinal study. J Headache Pain 22(Suppl 1):P287 (The International Headache Congress—IHS and EHF Joint Congress 2021) - PubMed
52. Vaghi G, Bitetto V, Guaschino E, De Icco R, Ghiotto N, Tassorelli C, Sances G (2021) Does erenumab suspension affect chronic migraine course? A real life experience. J Headache Pain 22(Suppl 1):P302 (The International Headache Congress—IHS and EHF Joint Congress 2021) - PubMed
53. Melo-Carrillo A, Strassman AM, Schain AJ, Manack Adams A, Brin MF, Burstein R (2021) Combined onabotulinumtoxin A/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons. Cephalalgia 41:17–32 - PubMed
54. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxin A: a retrospective chart review. Pain Ther 10(2):809–826 - PubMed
55. Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ, Krasenbaum LJ, Shen H, Stratton J (2021) Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain 22(1):3 - PubMed
56. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5‑year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716–1725 - PubMed
57. Rosen N, Pearlman E, Ruff D, Day K, Nagy AJ (2018) 100 % response rate to galcanezumab in patients with episodic migraine: a post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE‑1 and EVOLVE-2 studies. Headache 58:1347–1357 - PubMed
58. González-Quintanilla V, Pérez-Pereda S, González-Suárez A, Madera J, Toriello M, Pascual J (2021) Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: a report of two cases. Cephalalgia 41(11-12):1272–1275 - PubMed
59. Hamann T, Kamm K, Kropp P, Rimmele F, Jürgens TP (2020) Migräneprophylaxe – alles nur noch Antikörper? Schmerz 34:476–485. https://doi.org/10.1007/s00482-020-00500-x - PubMed
60. Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, Pittelkow MR, Mangold AR (2021) Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open 4(4):e217934 - PubMed
61. Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B, Irwin SL (2021) Calcitonin gene-related peptide monoclonal antibody use for the preventive treatment of refractory headache disorders in adolescents. Pediatr Neurol 114:62–67 - PubMed
62. Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41:789–798 - PubMed
63. Frank F, Ulmer H, Sidoroff V, Broessner G (2021) CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia 41(11-12):1222–1239 - PubMed
64. Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C, Maier-Peuschel M (2021) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. https://doi.org/10.1177/03331024211053571 - PubMed
65. Novartis (2020) Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention. Novartis, Basel - PubMed

Publication Types

• English Abstract
• Journal Article